ACAM2000™: The new smallpox vaccine for United States Strategic National Stockpile
Aysegul Nalca, Elizabeth E Zumbrun
Center for Aerobiological Sciences, US Army Medical Research Institute of Infectious Diseases (USAMRIID), Fort Detrick, MD, USA
Abstract: Smallpox was eradicated more than 30 years ago, but heightened concerns over bioterrorism have brought smallpox and smallpox vaccination back to the forefront. The previously licensed smallpox vaccine in the United States, Dryvax® (Wyeth Laboratories, Inc.), was highly effective, but the supply was insufficient to vaccinate the entire current US population. Additionally, Dryvax® had a questionable safety profile since it consisted of a pool of vaccinia virus strains with varying degrees of virulence, and was grown on the skin of calves, an outdated technique that poses an unnecessary risk of contamination. The US government has therefore recently supported development of an improved live vaccinia virus smallpox vaccine. This initiative has resulted in the development of ACAM2000™ (Acambis, Inc.™), a single plaque-purified vaccinia virus derivative of Dryvax®, aseptically propagated in cell culture. Preclinical and clinical trials reported in 2008 demonstrated that ACAM2000™ has comparable immunogenicity to that of Dryvax®, and causes a similar frequency of adverse events. Furthermore, like Dryvax®, ACAM2000™ vaccination has been shown by careful cardiac screening to result in an unexpectedly high rate of myocarditis and pericarditis. ACAM2000™ received US Food and Drug Administration (FDA) approval in August 2007, and replaced Dryvax® for all smallpox vaccinations in February 2008. Currently, over 200 million doses of ACAM2000™ have been produced for the US Strategic National Stockpile. This review of ACAM2000™ addresses the production, characterization, clinical trials, and adverse events associated with this new smallpox vaccine.
Keywords: smallpox, vaccinia, variola, vaccine, efficacy, safety
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Thilo S Lange, Carolyn McCourt, Rakesh K Singh, Kyu Kwang Kim, Ajay P Singh, et al
Published Date: 17 December 2008
Minoru Yamaoka, Yusuke Ono, Masahiro Takahashi, Ryosuke Doto, et al.
Published Date: 14 April 2009
Lily B Anderson, Phaedra B Anderson, Thea B Anderson, Amy Bishop, et al.
Published Date: 28 May 2009
Cecilia Becattini, Alessandra Lignani, Giancarlo Agnelli
Published Date: 7 April 2010
Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
Son V Pham, Phuong-Chi T Pham, Phuong-Mai T Pham, et al.
Published Date: 6 September 2010
Chimeric design, synthesis, and biological assays of a new nonpeptide insulin-mimetic vanadium compound to inhibit protein tyrosine phosphatase 1B
Thomas Scior, José Antonio Guevara-García, FJ Melendez, et al
Published Date: 23 September 2010
Laurie J Barten, Douglas R Allington, Kendra A Procacci, et al
Published Date: 24 November 2010
Marty Hinz, Alvin Stein, Thomas Uncini
Published Date: 28 February 2011
Comparison with ancestral diets suggests dense acellular carbohydrates promote an inflammatory microbiota, and may be the primary dietary cause of leptin resistance and obesity
Published Date: 6 July 2012
Nanostructured polyurethane-poly-lactic- co-glycolic acid scaffolds increase bladder tissue regeneration: an in vivo study
Yao C, Hedrick M, Pareek G, Renzulli J, Haleblian G, Webster TJ
Published Date: 28 August 2013